The expression of miR-126 and its host gene is reduced in most cancers including those with a high frequency of KRAS mutations such as colorectal cancer, lung cancer and pancreatic ductal carcinoma [55]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.